ROTH MKM downgraded Rain Oncology from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2023 | Buy → Neutral | ROTH MKM | |
| 3/21/2023 | $11.00 | Outperform | SVB Securities |
| 1/31/2023 | $21.00 | Buy | ROTH Capital |
| 1/23/2023 | $18.00 | Buy | Mizuho |
| 9/12/2022 | $10.00 | Buy | H.C. Wainwright |
| 4/1/2022 | $15.00 | Outperform | Oppenheimer |
| 9/14/2021 | $22.00 | Neutral | Goldman |
| 7/20/2021 | $25.00 | Overweight | Piper Sandler |
3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
424B3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
8-K - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
424B3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
NAPLES, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Rain Enhancement Technologies Holdco, Inc. (NASDAQ:RAIN) (the "Company") announced today that it received a notice (the "Notice") on August 19, 2025 from the Listing Qualifications Staff ("Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has not regained compliance with Nasdaq Listing Rule 5450(b)(2)(A), requiring the Company to maintain a market value of listed securities of at least $50 million, and Nasdaq Listing Rule 5450(b)(2)(B), requiring the Company to maintain a market value of publicly held shares of at least $15 million. The Notice provides that the Company has until 4:00 p.m. Eastern Time on August 26
Dot Ai (NASDAQ:DAIC) ("Dot Ai" or the "Company"), an IoT and AI-based SaaS startup at the forefront of Asset Intelligence technology, announced the appointment of two new members to its Board of Directors: Janice Bryant Howroyd and Walter Skowronski. Following the August 12th resignations of Directors Holly Grey and Joanna Burkey, Dot Ai's Board will remain comprised of 7 directors. Mr. Skowronski has been appointed as the chair of the audit committee and has been designated an "audit committee financial expert" under the relevant rules of the U.S. Securities and Exchange Commission "Janice and Walter each bring a wealth of expertise that will help us sharpen our strategy and strengthen e
Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Oncology Inc. (0001724979) (Issuer)
ROTH MKM downgraded Rain Oncology from Buy to Neutral
SVB Securities initiated coverage of Rain Oncology with a rating of Outperform and set a new price target of $11.00
ROTH Capital resumed coverage of Rain Oncology with a rating of Buy and set a new price target of $21.00
– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p
Dot Ai (NASDAQ:DAIC) ("Dot Ai" or the "Company"), an IoT and AI-based SaaS startup at the forefront of Asset Intelligence technology, announced the appointment of two new members to its Board of Directors: Janice Bryant Howroyd and Walter Skowronski. Following the August 12th resignations of Directors Holly Grey and Joanna Burkey, Dot Ai's Board will remain comprised of 7 directors. Mr. Skowronski has been appointed as the chair of the audit committee and has been designated an "audit committee financial expert" under the relevant rules of the U.S. Securities and Exchange Commission "Janice and Walter each bring a wealth of expertise that will help us sharpen our strategy and strengthen e
Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)